Benzinga | Nov 24, 2020 05:58AM EST

Goldman Sachs Initiates Coverage On Innate Pharma with Neutral Rating, Announces Price Target of $4.75

Goldman Sachs analyst Graig Suvannavejh initiates coverage on Innate Pharma (NASDAQ:IPHA) with a Neutral rating and announces Price Target of $4.75.